Agenus Inc. (NASDAQ:AGEN) Receives $14.00 Consensus Price Target from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have received an average rating of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $14.00.

AGEN has been the topic of a number of analyst reports. B. Riley restated a "buy" rating on shares of Agenus in a report on Monday, April 21st. Robert W. Baird raised their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. Wall Street Zen upgraded shares of Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright upgraded shares of Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price objective on the stock in a report on Wednesday, June 4th.

Agenus Stock Down 3.9%

Agenus stock traded down $0.21 during mid-day trading on Monday, reaching $5.16. 1,476,966 shares of the company's stock were exchanged, compared to its average volume of 662,478. The company has a market cap of $141.47 million, a P/E ratio of -0.46 and a beta of 1.43. Agenus has a twelve month low of $1.38 and a twelve month high of $18.74. The company has a fifty day moving average of $3.20 and a 200-day moving average of $3.01.

Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. Equities research analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AGEN. Corton Capital Inc. purchased a new position in shares of Agenus in the 4th quarter valued at $36,000. Apollon Wealth Management LLC grew its position in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after buying an additional 5,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Agenus in the 4th quarter valued at $51,000. Acadian Asset Management LLC purchased a new position in shares of Agenus in the 1st quarter valued at $58,000. Finally, Bank of Montreal Can purchased a new position in shares of Agenus in the 4th quarter valued at $69,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.